Patients with BRCA1/2 mutated cancers have better outcome following platinum-based chemotherapy than their non-BRCA1/2 mutated counterparts as their cells are incapable of repairing DNA double-strand breaks (DSBs), leading to sensitization to DNA-damaging agents [27,28]. The gene discussed is BRCA1; the disease is cancer.